Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Fineline Cube Jul 16, 2026
Company Deals

3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China

Fineline Cube Feb 17, 2025

China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...

Company Drug

LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites

Fineline Cube Feb 17, 2025

Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...

Company Drug

IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma

Fineline Cube Feb 17, 2025

China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...

Company Drug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Fineline Cube Feb 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...

Company Deals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Fineline Cube Feb 17, 2025

Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...

Company Drug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Fineline Cube Feb 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...

Company Drug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Fineline Cube Feb 17, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...

Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Fineline Cube Feb 16, 2025

In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...

Company

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing

Fineline Cube Feb 15, 2025

Beijing Wanjie Medical Device Co., Ltd. recently announced the successful completion of a B-round financing...

Company Digital

Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains

Fineline Cube Feb 15, 2025

On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector,...

Company

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures

Fineline Cube Feb 14, 2025

Hangzhou LinkZill Technology Co., Ltd. has recently completed a multi-million-dollar A-round financing, exclusively led by...

Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) of China has published the “Guidance Principles for Clinical...

Company Drug

Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study

Fineline Cube Feb 14, 2025

US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...

Company Drug

Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment

Fineline Cube Feb 14, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...

Company

GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials

Fineline Cube Feb 14, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) released its...

Company Drug

Betta Pharma Files for EMA Approval of ALK Inhibitor Ensartinib

Fineline Cube Feb 14, 2025

Betta Pharmaceuticals (SHE: 300558) announced the initiation of a market approval filing with the European...

Company Deals Drug

Lee Kai and Yangshun Partner on Polyvinyl Alcohol Embolization Microspheres

Fineline Cube Feb 14, 2025

Chinese companies Shanghai Lee Kai Technology Co., Ltd (Kai Medtech) and Hangzhou Yangshun Medical Technology...

Company Deals

Nanos Medical Raises Over RMB300m to Boost Otolaryngology Device Lead

Fineline Cube Feb 14, 2025

China-based Nanos Medical (Shanghai) Limited, an otolaryngology device maker, has reportedly raised over RMB300 million...

Company Drug

SciClone’s Vibativ Approved by NMPA for HABP/VABP Treatment

Fineline Cube Feb 14, 2025

China-based SciClone Pharmaceuticals Inc. announced that it has received market approval from the National Medical...

Company Deals

Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA

Fineline Cube Feb 14, 2025

China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody...

Posts pagination

1 … 242 243 244 … 696

Recent updates

  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.